Monday, July 20, 2020 7:57:19 PM
The knowledge from NASH morphed into the AGN concepts and has thoughtful scientific R+D along with strong leadership and a big company's visions. IMO. AGN's other 'pipeline' drugs, with their repurposed science, also are to be tested eventually too. People have posted about Kidney issues from COVID and the possible relevance of AGN's drugs.
Licensing and partnerships await any company with 'near term' Proven COVID associated successes. IMO. Maybe even 'Fast Track' status thru the USFDA, grants.
Not to mention the - CKD - IBD future is separate from COVID/IPF/CC/ALI, which I just did. LOL.
From here - AGN - we can see crystal ball possibilities, IMO...GLTA...
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM